Data published on line in the Journal of Urology last December suggest that the new PDE5 inhibitor known as avanafil or Stendra® is supposedly effective in combating erectile dysfunction (ED) in just over one-third of men with ED at 6 months after bilateral, nerve-sparing radical prostatectomy. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: avanafil, ED, efficacy, erectile dysfunction, prostatectomy, safety | 7 Comments »
There are few published data on the efficacy and safety of PDE-5 inhibitors (e.g., sildenafil/Viagra and tadalafil/Cialis) in management of erectile function after the first-line treatment of prostate cancer with radiation therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: erectile dysfunction, radiation therapy, tadalafil | Leave a comment »
It has long been understood that erectile function after first-line treatment for localized prostate cancer is affected by (a) erectile function before treatment and (b) elapsed time after treatment. However, the available data offering a careful analysis of the chronology of erectile function after first-line treatment of localized prostate cancer has been limited. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: brachytherapy, erectile dysfunction, erectile function, time | Leave a comment »
A recent report from John Mulhall’s group at Memorial Sloan-Kettering Cancer Center has provided data on the use of surgical implantation of penile prostheses for management of erectile dysfunction after treatment for prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: ED, erectile dysfunction, implant, penile, prosthesis, surgery | 1 Comment »
It is unlikely to come as any big surprise to the average prostate cancer patient who was potent before first-line therapy but has erectile dysfunction (ED) afterward that there might be an association between ED and depression after initial treatment for localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: depression, ED, erectile dysfunction | 6 Comments »
In July this year, we commented on the 14-year mortality data published by Hugosson et al. from the randomized, population-based, prostate cancer screening trial initiated in Göteborg, Sweden, in 1995. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: erectile dysfunction, incontinence, morbidity, radical prostatectomy, screening, side effects | 2 Comments »
A new study from a German research group is likely to fuel concerns about some of the risks associated with prostate biopsy. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, complications, ED, erectile dysfunction, voiding | 12 Comments »
Today’s news reports address:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: diabetes, endorectal coil, erectile dysfunction, MRI, penile rehabilitation, radiotherapy, risk | Leave a comment »
We have commented previously on the increasing number of papers that appear to be looking with greater clarity at issues related to the adverse consequences of prostate cancer therapy. A new paper on the impact of “sexual bother” (for which you can read “physical or psychological distress related to sexual intercourse”) appears to be another paper in this “series.” … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: erectile dysfunction, radical prostatectomy, RP, sexual bother | 2 Comments »
According to a company press release issued earlier today by VIVUS, Inc., avanafil, an investigational agent, was effective in the treatment of erectile dysfunction (ED) in some 77 percent of patients at a dose of 200 mg. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: avanafil, ED, erectile dysfunction | 5 Comments »
The American College of Physicians (ACP) has just issued new guidelines that strongly endorses use of sildenafil (Viagra) and similar drugs for the treatment of erectile dysfunction (ED). … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: erectile dysfunction, guideline, PDE5 inhibitor | Leave a comment »
There is extensive promotion of the various forms of radical prostatectomy as a method for the treatment of prostate cancer. However, it would be fair to say that the supposed benefits of treatment are normally given a great deal more prominence than the very real risks. … READ MORE …
Filed under: Management, Treatment | Tagged: erectile dysfunction, promotion, radical prostatectomy. web sites, RALP | 1 Comment »
Risk for erectile dysfunction (ED) after prostate cancer treatment is commonly assumed to be a reason why many men avoid being tested for their risk for prostate cancer. Whether that is really true or not is actually not well understood. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: ED, erectile dysfunction, screening | Leave a comment »
According to a media release from Eli Lilly and Company late yesterday, a double-blind, placebo-controlled study has shown that tadalafil (Cialis) 5 mg taken once daily improved erectile function for men with erectile dysfunction (ED) and reported improvement in the sexual quality of life scores for men and their female partners. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: erectile dysfunction, partner, sexual quality of life, tadalafil | 2 Comments »
Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra) are now used regularly as a means to treat patients with erectile dysfunction (ED) following radiation therapy (RT) for localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ED, erectile dysfunction, radiation therapy, sildenafil | 6 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 